Research Article

Stable Instability of Sarcoma Cell Lines Genome Despite Intra-Tumoral Heterogeneity: A Genomic and Transcriptomic Study of Sarcoma Cell Lines

Lagarde P[1,2], Brulard C[1], Pérot G[1,3], Mauduit O[1], Delespaul L[1], Neuville A[1,3], Stoeckle E[4], Le Guellec S[5], Rochaix P[5], Coindre JM[1,2,3] and Chibon F[1,3]*

[1]INSERM U916, France
[2]Bordeaux University, France
[3]Department of Biopathology, Institut Bergonié, Comprehensive Cancer Centre, France
[4]Department of Surgery, Institut Bergonié, Comprehensive Cancer Centre, France
[5]Departement of Pathological Anatomy and Cytology, Oncopole, 1 avenue Irène Joliot-Curie, France

*Corresponding author: Frédéric Chibon, Tumor Genetics - Department of Biopathology and INSERM U916, Genetics and Biology of Sarcomas, Insitut Bergonié, 229 cours de l'Argonne, 33076 Bordeaux, France

Abstract

Background: Sarcoma oncogenesis is still poorly understood and functional studies are hampered by the dearth of cell lines representative of diverse sarcoma types. The existing models suffer from two main pitfalls: lack of representativeness of the tumors from which they were derived and lack of information about their evolution over passages. There is therefore a pressing need to generate new cell lines.

Methods: All sarcoma tumors from patients receiving surgery in a large tertiary referral center in France were cultured to establish the corresponding cell lines. We performed comparative genomic and transcriptomic studies of the original tumor and cell lines to evaluate the representativeness of the cell line to the original tumor and evolution over passages.

Results: Pleomorphic sarcomas are genetically heterogeneous. As a consequence, cell lines derived from that kind of tumor developed from selected clones roughly representing the initial tumor. More importantly, our results show that there are no genetic imbalances and transcription modifications along passages.

Conclusion: Even if pleomorphic sarcomas are genetically unstable at the cellular level, they appear to be genetically stable at the multicellular one, and therefore remain representative of the initial tumor even after passages. We established a sarcoma cell line panel gathering 32 cell lines with genomic, transcriptomic and clinical data, which will be significant to understand genomic alterations, sarcoma biology and to manage preclinical studies and clinical trials.

Keywords: Cell lines; Heterogeneity; Instability; Sarcoma

Introduction

Soft Tissue Sarcomas (STS) are a heterogeneous group of mesenchymal tumors that account for 1-2% of all cancers. More than 100 types and subtypes of sarcomas are listed by the World Health Organization (WHO). Metastatic risk depends on histological type and varies from 20% to 60% [1], meaning that an accurate initial diagnosis is essential for patient clinical management.

Based on cytogenetic and Comparative Genomic Hybridization (CGH) data, sarcomas can be divided into two main groups: one characterized by known alterations such as translocation t(11;22) (q24;q12) in Ewing sarcomas [2], t(X;18) in synovialosarcomas [3,4], mutation in Gastrointestinal Stromal Tumors (GIST) [5,6] or amplifications as MDM2/CDK4 in dedifferentiated and well-differentiated liposarcomas [7,8]; and a second group of sarcomas without known alterations and with complex genetics, including leiomyosarcomas and undifferentiated pleomorphic sarcomas [9-11].

Although considerable genomic and transcriptomic data are currently available for sarcomas [11-14], oncogenesis is still poorly understood. In order to better understand sarcoma biology, to determine the involvement of a gene and to develop a therapeutic target, genomics-guided functional genetic studies are necessary.

Yet, functional studies in sarcomas are hampered by the dearth of appropriate models. Only a limited number of human sarcoma cell lines exist, in part because of the rarity of certain diagnoses and resulting scarcity of samples. Moreover, for each of the subtypes with complex genomes, multiple cell lines are needed to represent the diversity of genetic alterations within that subtype. Several large-scale projects now aim to genetically characterize large numbers of human cancer cell lines and screen these against a range of anticancer therapies to correlate drug sensitivity with genetic markers [15]. Among these are the Cancer Cell Line Encyclopedia and the Sanger Cancer Cell Line Project. The Sanger project is assembling approximately 800 cell lines, of which only 10 (1.3%) represent complex soft-tissue sarcomas. As a result, there is a real need to generate cell lines representative of diverse sarcoma types, mainly for the subtypes with complex karyotypes. The creation of a sarcoma cell line panel with genomic and transcriptomic profiles that mirror the diversity observed in their corresponding tumor types would represent a critical step in understanding the influence of heterogeneity on variability of response to targeted therapies [16]. Such a panel could also drive genomics-guided functional genetics, either with arrayed or pooled loss-of-function RNAi screens [17,18], or 'ORFeome' approaches [19,20].

To address this issue, we cultured sarcoma tumor cells from every patient treated by surgery at the Institut Bergonié, a large tertiary referral center in France. Among the 32 established cell lines, we performed genomic and transcriptomic studies on seven of them to evaluate the representativeness of the original tumor and the evolution over more than 50 passages.

Materials and Methods

Ethics statement

The samples used in this study were part of the Biological Resources Center of Bergonie Cancer Institute (CRB-IB). In accordance with the French Public Health Code (articles L. 1243-4 and R. 1243-61), the CRB-IB received the agreement from the French authorities to deliver samples for scientific research (number AC-2008-812, on February 2011). These samples were obtained from regular patient care and requalified for research. Patients provided written informed consent approved by the Committee of Protection of Individuals.

Establishing a cell line

Following surgical resection, fresh tumor tissue was minced with scissors and then digested with 200 IU/ml type II collagenase (Roche) in serum-free RPMI 1640 with glutamax, supplemented with antibiotics (Gibco BRL, Life Technologies) overnight. After digestion, isolated cells and pieces were washed and seeded in a 25cm2 plastic flask containing culture medium, and maintained in a humidified atmosphere of 5% CO_2 at air temperature of 37°C. The culture medium was composed of a RPMI 1640 with glutamax (Gibco BRL, Life Technologies, Cergy Pontoise, France) supplemented with 10% fetal calf serum and 1% antibiotics (penicilline /streptomycine, Gibco BRL, Life Technologies, Cergy Pontoise, France). All cell lines were tested for mycoplasma by Polymerase Chain Reaction (PCR) (Sigma; Look Out Mycoplasma PCR Detection Kit) according to manufacturer's recommendations.

Cell sorting by flow cytometry

Cells from a culture flask were collected into a conical tube and centrifuged at 400g for 5 min. The supernatant was discarded and the pellet was resuspended in medium (cell culture medium Or Phosphate-Buffered Saline [PBS] with 1% bovine serum albumin). Cells were counted and resuspended at an appropriate concentration, in the range of 106–107 per mL.

The pellet was resuspended in 5 mM EDTA (ethylene-diamine-tetra-acetic-acid). Cells were isolated by FACS Aria [BD Biosciences, San Jose, CA], every cell isolated was placed in a well of 96-wells plate.

Nucleic acid isolation

DNA from the cell lines and from snap-frozen tumors was isolated for Comparative Genomic Hybridization (CGH). Genomic DNA was isolated with a standard phenol-chloroform extraction protocol after Rnase treatment. Total RNA for gene expression studies was extracted from cell lines (before passage 20 and after passage 30) and from frozen tumor samples with TRIzol reagent (Gibco BRL, Life Technologies) and purified with the RNeasy Min Elute Cleanup Kit (Qiagen, Courtaboeuf, France) according to the manufacturer's procedures. We checked RNA quality on an Agilent 2100 bioanalyzer (Agilent Technologies, Massy, France) according to the manufacturer's recommendations.

Array-CGH analysis

DNA was hybridized to 8 x 60K whole-Genome Agilent Arrays (G4450A) according to the manufacturer's protocol. The ADM-2 algorithm of Agilent Genomic Workbench Lite Edition 6.5.0.18 was used to identify DNA copy number anomalies at the probe level. A low-level copy number gain was defined as a log 2 ratio >0.25 and a copy number loss was defined as a log 2 ratio <-0.25. A high-level gain or amplification was defined as a log 2 ratio >1.5 and a homozygous deletion was suspected when the ratio was < -1.

Gene expression profiling

Gene expression analysis was carried out using Agilent Whole human 44K Genome Oligo Array (Agilent Technologies) according to the manufacturer's protocol. All microarrays were simultaneously normalized using the Quantile algorithm. T-tests were performed using Gene Spring (Agilent Technologies) and P-values were adjusted using the Benjamini-Hochberg procedure. The P-value and fold change cut-off for gene selection were 0.001 and 3, respectively. Gene Ontology (GO) analysis was performed to establish statistical enrichment in GO terms using Genespring (Agilent Technologies, Massy France).

Statistical analysis

Genomic normalized data files were formatted to obtain 55077 unique probes and in case of duplicate probes the mean value was retained. Pearson's correlations and graphs were established with R software version 2.14.1. For transcriptomic normalized data files, we excluded controlling probes, and selected unique probes for each gene by maximum Inter Quartile Range (IQR) on R environment. Overall, 30995 probes were used to perform Hierarchical Ascending Classification (HAC) with the Ward method using the "cluster" R library. The agglomerative coefficient is 0.54 for tumor/cell line analysis and 0.61 for early cell lines/late cell lines analysis.

Results

From 2009 to 2012, surgery specimens of malignant mesenchymal tumors of every patient treated at Bergonié Institute were cultured and 32 cell lines were established from 134 tumor samples submitted to cell culture (24%; Supplementary Table S1).

To test whether sarcoma cell lines were representative of their matching tumor and whether their genomic and transcriptomic profile was stable during passages, seven cell lines (Table 1) were characterized at early and late passages and compared to their matching tumor.

Are cell lines representative of their matching tumor?

Genome profiling was performed from DNA extracted at p50 (50 passages is widely accepted as a threshold to declare an established cell line). All cell lines harbored a genomic profile characteristic of the tumor histotype from which they were derived. IB105 and IB106 were derived from an undifferentiated sarcoma and presented highly rearranged genomes (Figure 1), as well as IB114, IB116 and IB117, which were derived from myxofibrosarcomas (Figure 2). IB111 and IB115, established from Dedifferentiated Liposarcomas (DDLPS), were characterized by an amplicon profile with a characteristic MDM2 and CDK4 amplification and a moderately rearranged genome (Figure 3). Comparing these cell line profiles to those of each

Table 1: Clinicopathological data of the tumors from which cell lines were established and type of cell lines and their corresponding tumor tissues genomic profile.

| Patient	Sex	Age (y)	Histological diagnosis	Site	FNCLCC Grading	Tumor CGH profile	Cell line CGH profile	Follow-up
IB105/ IB106	female	79	unclassified sarcoma	paravertebral	3	complex	complex	DOD (Dead of Disease)
IB111	female	83	dedifferentiated liposarcoma	axillary	3	amplicons (among them : MDM2,CDK4)	complex with amplicons (MDM2,CDK4)	ductal carcinoma infiltrative
IB115	male	75	dedifferentiated liposarcoma	paratesticular	3	amplicons (among them : MDM2, CDK4)	amplicons (MDM2, CDK4)	lost to follow-up
IB114	female	90	myxofibrosarcoma	left thigh	3	complex with arms	complex with arms	DOD (Dead of Disease)
IB116	male	81	myxofibrosarcoma	left thigh	2	flat	complex with arms	lost to follow-up
IB117	female	58	myxofibrosarcoma	right thigh	3	complex	complex	alive without disease

Figure 1: Genomic profiles of undifferentiated sarcoma established cell lines a) IB105, b) IB106 and the corresponding tumor: red profiles corresponding to tumor profile and black profiles corresponding to cell line p50.

Figure 2: Genomic profiles of myxofibrosarcomas established cell lines and the corresponding tumor: red profiles corresponding to tumor profile and black profiles corresponding to cell line p50.

matching tumor, even if we identified patterns of common alteration profiles, we observed that a few alterations were exclusive to either the cell line or the tumor. Both myxofibrosarcoma (IB114 and IB117) and DDLPS (IB111 and IB115) cell line profiles were similar to those

Figure 3: Genomic profiles of dedifferentiated liposarcomas established cell lines and the corresponding tumor: red profiles corresponding to tumor profile and black profiles corresponding to cell line p50.

Figure 4: Gene expression profiles of late cell lines and corresponding tissue. a) Unsupervised clustering on 30 995 probes b) Unsupervised clustering on 12 695 probes, number total of probes minus probes differentially expressed between cell line and tumors (*P*< 0.05) and genes associated to 451 GO enriched L: late culture.

of the matching tumors (Figures 2 and 3), but for IB105 and IB106, which were derived from one undifferentiated sarcoma, genomic profiles were clearly different (Figure 1) even if a large part of the alterations was shared.

To evaluate the representativeness of the cell line at the transcriptomic level, we carried out unsupervised clustering of the transcriptomic profiles of all cell lines and tumors (Figure 4a). The samples were split into two groups: cell lines and tumors, with a large distance between the two entities. Among the 15433 probes differentially expressed (P <0.05) between cell lines and tumors, 9939 probes were up-regulated in the cell lines whereas 5494 were down-regulated. Regarding the 9939 up-regulated probes, GO analysis (Supplementary Table S2a) identified 178 enriched GO terms (P <0.05), with the most frequent being mitosis and cell cycle. Regarding the 5494 down-regulated probes in the cell lines, GO analysis (Supplementary Table S2b) identified 273 enriched GO terms (P <0.05), with the top ranked being associated with immune response and cell adhesion. Considering that these differentially expressed genes and enriched pathways were associated with the in-vitro cell

culture conditions and not with the tumor cell biology, we performed a second unsupervised clustering removing both the 15433 probes differentially expressed and the genes associated with the 451 GO terms differentially enriched. Four of the seven cell lines (IB105, IB106, IB114 and IB117) clustered with their matching tumor (Figure 4b).

Do cell line genome and transcriptome evolve in culture?

To test whether the cell line genome can evolve in vitro, we performed a genome profiling of each cell line every 10 passages. To evaluate the slight variation associated to technical variability, we performed two genomic profiles per sample, on seven samples, in two independent experiments (extraction and array-CGH) and we calculated the correlation coefficients (r) between the two profiles of the same sample (data not shown). This experiment enabled us to consider two genomic profiles identical when the correlation coefficient was higher than 0.93 [range: 0.93 to 0.99].

For all cell lines, the genomic profiles are similar from p10 to p50 (Figure 5), with correlation coefficients ranging from 0.9 to 0.98 from

Figure 5: a) IB117 genomic profiles at p10, p20, p30, p40, p50. b) IB106 genomic profiles at p10, p20, p30, p40, p50.

p20 to p50 (Table 2). Nevertheless, for IB106, we observed a slight difference between profiles from p10 to p20 (correlation coefficient = 0.66), whereas profiles at later passages were highly correlated (correlation coefficient >0.94). These results indicate that no genomic changes occur during cell culture as demonstrated by CGH profiling.

We performed two expression profiling experiments for each cell line, one in early and one in late stages of culture with at least 20 passages between the two profiles. Unsupervised clustering showed that early and late gene expression profiles for each of the IB114, IB115, IB111, IB116 and IB117 cell lines clustered together (Figure 6). For IB105 and IB106 on the other hand, the early passages of both cell lines and the late passages of both cell lines clustered together.

## Does observed genome stability keep Intra-tumoral heterogeneity hidden?

The aim of our study was to investigate the intra-tumoral

hetereogeneity that probably causes differences between original tumor and matching cell line genomes.

Two cell lines with distinct genetics, IB106 (undifferentiated

Table 2: Pearson's correlation coefficient for each cell line between one passage and the previous one. p = passage.

	p10 vs. p20	**p20 vs. p30**	**p30 vs. p40**	**p40 vs. p50**
IB105	0.99	0.98	0.96	0.96
IB106	0.66	0.94	0.95	0.98
IB111	0.83	0.93	0.90	0.92
IB114	0.94	0.98	0.94	0.90
IB115	0.96	0.89	0.95	0.95
IB116	0.92	0.94	0.95	0.98
IB117	0.97	0.95	0.91	0.95

Figure 6: Gene expression profiles of cell lines at early culture and at late culture. Clustering on 30 995 probes E: early culture L: late culture.

sarcoma) and IB115 (DDLPS) were sub-cloned at the single cell level. 12/96 (12.5%) and 21/96 (22%) isolated single cells from IB106 and IB115, respectively, underwent clonal expansion. CGH profiling of these individual clones revealed that IB106 sub-clones were all super imposable to the IB106 cell line (Figure 7a) with a correlation coefficient ranging from 0.92 to 0.99. In contrast, the genome of the IB115 sub-clone differed from that of the cell line with many specific alterations present only in the cell line or only in one clone (Figure 7b). Accordingly, the correlation coefficient interval dropped to 0.71 to 0.92. As evidenced in primary cell lines and evaluated by CGH, the sub-clone genomes did not show any significant variation at passages 2, 10 and 15 post sub-cloning (0.9 <r<0.97).

Discussion

Currently, clinical management of STS consists mainly of surgical resection with adjuvant therapies that depend on surgical margins and tumor histological type and grade. No targeted therapy is currently available, except for GISTs with imatinib mesylate (Gleevec, Novartis Pharma AG) [21]. The main breakthrough leading to a targeted therapy would first be the identification of a recurrent genomic alteration and then, its biological characterization. Furthermore, in vitro cell lines with human xenograft models may be useful in understanding the biology of this tumors and predicting drug response [22]. Even if some models are already available, they suffer from two main pitfalls: lack of representativeness of the tumors from which they were derived; and lack of information about their evolution over passages.

We evaluated the genomic representativeness of several cell lines by comparing genomic and transcriptomic profiles from the cell lines and the original tumors. Our results indicate that the main oncogenic events are identical in the tumor and matching cell line (eg, MDM2 and CDK4 amplifications in DDLPS, RB1 loss in US and MFS). As reported by Wistuba et al. [23,24] in lung and breast cancers, in our series, four cell lines (IB105, IB106, IB114 and IB117) are genetically

representative of their corresponding tumors. Among them, two are undifferentiated sarcomas and two are myxofibrosarcomas. The two undifferentiated sarcoma cell lines are derived from the same tumor so the three genomic profiles have similar alterations (1q, 2qter, 5p, loss of chromosome 10, 11p, 12p, 13, and 16) but some alterations are specific to each cell line. The IB105 cell line genomic profile retains its similarities with the IB105-106 tumor genomic profile over time, and is pure in early passages (before passage 10). The IB106 cell line genomic profile has a weak correlation coefficient with its corresponding tumor genomic profile at passage 10. After passage 10, the correlation coefficients between passages increase and stabilize, demonstrating that the same similarity of the two genomic profiles (tumor and each passage) is stable through time. This probably means that at early passages this cell line is contaminated by other clones or non-tumoral cells and, that cells or clones composing the cell line reach a stabilization of their relative proportions between passage 20 and passage 30.

The IB114 cell line retains the genomic features of the original tumor. However, the correlation coefficient decreases over passages. This can be explained by a contamination of non-tumoral cells, clonal selection, or both.

Cell line genomic profiles show only a few alterations that are more frequently represented than in the corresponding tumor genomic profiles: deletion of CDKN2a and RB1, gains on chromosome 12, and alterations specific to the cell line: gains on chromosome 5, and chromosome 8q. Other common alterations are less frequent in the cell line than in the corresponding tumor. This observation permits us to conclude that there is an in vitro clonal selection.

To evaluate the transcriptomic representativeness of the cell lines in relation to the original tumor at late passages, we compared their transcriptomic profiles. Two different clusters were identified: tumors and cell lines. As for Gottschling et al. [25,26], GO analysis on 15 433 probes differentially expressed between the two entities, showed mitosis and cell cycle to be overexpressed in the cell lines, and immune response, adhesion, proliferation, differentiation and angiogenesis to be under expressed. All these deregulated pathways are linked to microenvironments. Communication between cells and their microenvironments occurs through a complex network of signals generated by cell-extracellular matrices and cell-cell adhesion and junctional molecules, as well as by collaboration between epithelial, stroma and other organ-specific cell types [27].

However, there were also common gene expression patterns showing the relationship between cell lines and their corresponding tumor tissues with cell lines being representative of the tumor in terms of oncogenic pathways. This is confirmed by the clustering of probes remaining after removing the most differentially expressed genes and GO terms. Four of the seven pairs clustered together. These four cell lines (IB105, IB106, IB114 and IB117) have transcriptional programs close to their corresponding tumors.

IB111 and IB115 cell lines, derived from DDLP, have genomic profiles close to their corresponding tumors but a cell line expression profile distinct from their matching tumors. However the MDM2/ CDK4 over-expression is found in both the cell line and the corresponding tumor expression profiles. The IB111 tumor genome is less prone to rearrangement than the cell line genome, however, in

Figure 7: a) Genomic profiles of five IB106 clones, b) Genomic profiles of five IB115 clones. Arrows indicate main imbalance differences.

the tumor genomic profile, all alterations detected are also detected in the cell line genomic profile but less represented. This observation suggests a contamination of non-tumoral cells in the tumor.

Alterations present in the IB115 tumor genome are also observed in its corresponding cell line except for two amplicons on chromosome 6, one amplicon on chromosome 8 and the loss of chromosome 13. In the cell line genomic profile we can observe an alteration not detected in its tumor genomic profile. On this cell line, we performed clonal selection, and after amplification, we established the genomic profile of each clone. This experiment showed genomic profiles with common alterations (amplicons) and with some clone specific alterations (data not shown). The IB115 cell line represents a pool of clones of the IB115 tumor.

The contamination by non-tumoral cells for IB111 and by others clones for IB115 explain why their global expression profiles did

not cluster with their corresponding cell lines. Concerning IB116, profiling experiments showed that the tumor genome was flat and the cell line genome rearranged. The diagnosis of IB116 tumor is myxofibrosarcoma, which is characterized by complex genomics; the karyotypic abnormalities are multiple numerical and structural rearrangements [28,29]. We can conclude from these observations that the flat tumor genomic profile of IB116 shows a strong contamination by non-tumoral cells.

For the seven established cell lines, genomic profiles are stable across passages in our culture conditions. Furthermore, for two cell lines (IB106/IB111), we can observe purification over time, which is illustrated on the IB106 genomic profile by the increasing detection of the chromosome 13 loss. A clonal in vitro selection is induced from culture conditions, so one or several clones of the original tumor have the capacity to adapt to the new environment [30,31].

Trancriptomic profiles are stable across time for five cell lines. Indeed, the transcriptomic profiles of the same cell line clustered together, even if in early stages the cell line was contaminated by non-tumoral cells or by other clones. For two cell lines, IB105/IB106, the two early transcriptomic profiles clustered together and the two late transcriptomic profiles clustered together, which is probably because the IB105/106 cell lines arose from the same original tumor so one was certainly contaminated by the other one and in late stages only one clone survived. However, the transcriptomic profiles stay close over time. These experiments indicate that the cell lines' genomic and transcriptomic profiles are stable across time.

Overall, results strongly suggest that among the intra-tumoral heterogeneity, a subset of clones establish in culture, creating a heterogeneous cell line more or less representative of the tumor depending on the intra-tumoral heterogeneity of the initial tumor. However, after this first selection step allowing culture establishment, the cell line, even if heterogeneity remains, is genetically stable across passages, in non-modified cell culture conditions. This probably means that, even if pleomorphic sarcomas are clearly genetically unstable at the cellular level, they appear to be genetically stable at the multicellular one.

This study allows us to extrapolate these genomic and transcriptomic stabilities across time, to other cell lines established in our lab. Since 2009, we have systematically submitted to cell culture every sarcoma resected at the Institut Bergonié Cancer Centre. The aim of the project is to develop a cell line bank. For all cell lines, genomic, transcriptomic and clinical data are available. At present, we have established 32 sarcoma cell lines (Supplemental Table S1). Therefore, a panel of sarcoma cell lines is now available that will be crucial to further understand genomic alterations, sarcoma biology and to manage preclinical studies and clinical trials.

Acknowledgement

References

1. Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F. Pathology and genetics of tumors of soft tissue and bone. World Health Organization Classification of Tumors. Lyon: IARC Press. 2013.

2. Turc-Carel C, Aurias A, Mugneret F, Lizard S, Sidaner I, Volk C, et al. Chromosomes in Ewing's sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11;22)(q24;q12). Cancer Genet Cytogenet. 1988; 32: 229-238.

3. Limon J, Dal CP, Sandberg AA. Translocations involving the X chromosome in solid tumors: presentation of two sarcomas with t(X;18)(q13;p11). Cancer Genet Cytogenet. 1986; 23: 87-91.

4. Turc-Carel C, Dal CP, Limon J, Li F, Sandberg AA. Translocation X;18 in synovial sarcoma. Cancer Genet Cytogenet. 1986; 23: 93.

5. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-580.

6. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003; 299: 708-710.

7. Chibon F, Mariani O, Derre J, Malinge S, Coindre JM, Guillou L, et al. A subgroup of malignant fibrous histiocytomas is associated with genetic changes similar to those of well-differentiated liposarcomas. Cancer Genet

8. Coindre JM, Mariani O, Chibon F, Mairal A, De Saint Aubain SN, Favre-Guillevin E, et al. Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas: a review of 25 cases initially diagnosed as malignant fibrous histiocytoma. Mod Pathol. 2003; 16: 256-262.

9. Chibon F, Mariani O, Mairal A, Derre J, Coindre JM, Terrier P, et al. The use of clustering software for the classification of comparative genomic hybridization data. an analysis of 109 malignant fibrous histiocytomas. Cancer Genet. Cytogenet. 2003; 141: 75-78.

10. Derre J, Lagace R, Nicolas A, Mairal A, Chibon F, Coindre JM, et al. Leiomyosarcomas and most malignant fibrous histiocytomas share very similar comparative genomic hybridization imbalances: an analysis of a series of 27 leiomyosarcomas. Lab Invest. 2001; 81: 211-215.

11. Idbaih A, Coindre JM, Derré J, Mariani O, Terrier P, Ranchère D, et al. Myxoid malignant fibrous histiocytoma and pleomorphic liposarcoma share very similar genomic imbalances. Lab Invest. 2005; 85: 176-181.

12. Nielsen TO, West RB, Linn SC, Alter O, Knowling MA, O'Connell JX, et al. Molecular characterisation of soft tissue tumours: a gene expression study. Lancet. 2002; 359: 1301-1307.

13. Baird K, Davis S, Antonescu CR, Harper UL, Walker RL, Chen Y, et al. Gene expression profiling of human sarcomas: insights into sarcoma biology. Cancer Res. 2005; 65: 9226-9235.

14. Fritz B, Schubert F, Wrobel G, Schwaenen C, Wessendorf S, Nessling M, et al. Microarray-based copy number and expression profiling in dedifferentiated and pleomorphic liposarcoma. Cancer Res. 2002; 62: 2993-2998.

15. Chibon F, Lagarde P, Salas S, Perot G, Brouste V, Tirode F, et al. Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat Med. 2010; 16: 781-787.

16. Bignell GR, Greenman CD, Davies H, Butler AP, Edkins S, Andrews JM, et al. Signatures of mutation and selection in the cancer genome. Nature. 2010; 463: 893-898.

17. Sharma SV, Haber DA, Settleman J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer. 2010; 10: 241-253.

18. Luo B, Cheung HW, Subramanian A, Sharifnia T, Okamoto M, Yang X, et al. Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci. USA. 2008; 105: 20380-20385.

19. Moffat J, Grueneberg DA, Yang X, Kim SY, Kloepfer AM, Hinkle G, et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell. 2006; 124: 1283-1298.

20. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010; 468: 968-972.

21. Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. Lancet. 2007; 369: 1731-1741.

22. Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res. 2003; 9: 4227-4239.

23. Wistuba II, Bryant D, Behrens C, Milchgrub S, Virmani AK, Ashfaq R, et al. Comparison of features of human lung cancer cell lines and their corresponding tumors. Clin Cancer Res. 1999; 5: 991-1000.

24. Wistuba II, Behrens C, Milchgrub S, Syed S, Ahmadian M, Virmani AK, et al. Comparison of features of human breast cancer cell lines and their corresponding tumors. Clin Cancer Res. 1998; 4: 2931-2938.

25. Gottschling S, Jauch A, Kuner R, Herpel E, Mueller-Decker K, Schnabel PA, et al. Establishment and comparative characterization of novel squamous cell non-small cell lung cancer cell lines and their corresponding tumor tissue. Lung Cancer. 2012; 75: 45-57.

26. Zanazzi C, Hersmus R, Veltman IM, Gillis AJ, van DE, Beverloo HB, et al.

Cytogenet. 2002; 139: 24-29.

Gene expression profiling and gene copy-number changes in malignant mesothelioma cell lines. Genes Chromosomes. Cancer. 2007; 46: 895-908.

27. Bissell MJ, Hines WC. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med. 2011; 17: 320-329.

28. Ohguri T, Hisaoka M, Kawauchi S, Sasaki K, Aoki T, Kanemitsu S, et al. Cytogenetic analysis of myxoid liposarcoma and myxofibrosarcoma by array-based comparative genomic hybridisation. J Clin Pathol. 2006; 59: 978-983.

29. Mairal A, Chibon F, Rousselet A, Couturier J, Terrier P, Aurias A.

Establishment of a human malignant fibrous histiocytoma cell line, COMA. Characterization By conventional cytogenetics, comparative genomic hybridization, and multiplex fluorescence In situ hybridization. Cancer Genet. Cytogenet. 2000; 121: 117-123.

30. Gisselsson D. Intratumor diversity and clonal evolution in cancer--a skeptical standpoint. Adv Cancer Res. 2011; 112: 1-9.

31. Kanzaki T, Kitajima S, Suzumori K. Biological behavior of cloned cells of human malignant fibrous histiocytoma *in vivo* and *in vitro.* Cancer Res. 1991; 51: 2133-2137.